HL Financial Services LLC raised its holdings in ABIOMED, Inc. (NASDAQ:ABMD) by 44.3% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 38,887 shares of the medical equipment provider’s stock after buying an additional 11,944 shares during the quarter. HL Financial Services LLC owned approximately 0.09% of ABIOMED worth $17,489,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also bought and sold shares of ABMD. Principal Financial Group Inc. grew its holdings in ABIOMED by 2.9% in the 1st quarter. Principal Financial Group Inc. now owns 183,416 shares of the medical equipment provider’s stock valued at $53,372,000 after buying an additional 5,158 shares during the period. Cerebellum GP LLC purchased a new stake in ABIOMED in the 2nd quarter valued at about $151,000. Gulf International Bank UK Ltd purchased a new stake in ABIOMED in the 2nd quarter valued at about $5,645,000. IFM Investors Pty Ltd purchased a new stake in ABIOMED in the 2nd quarter valued at about $765,000. Finally, CENTRAL TRUST Co grew its holdings in ABIOMED by 35.5% in the 2nd quarter. CENTRAL TRUST Co now owns 3,425 shares of the medical equipment provider’s stock valued at $1,401,000 after buying an additional 898 shares during the period. Institutional investors own 87.14% of the company’s stock.
Several research firms have recently weighed in on ABMD. BidaskClub raised ABIOMED from a “hold” rating to a “buy” rating in a research note on Wednesday, September 5th. ValuEngine lowered ABIOMED from a “strong-buy” rating to a “buy” rating in a research note on Saturday, August 18th. Zacks Investment Research raised ABIOMED from a “hold” rating to a “buy” rating and set a $457.00 price objective on the stock in a research note on Tuesday, July 10th. BTIG Research raised ABIOMED from a “neutral” rating to a “buy” rating and set a $450.00 price objective on the stock in a research note on Friday. Finally, Morgan Stanley lifted their price objective on ABIOMED from $370.00 to $396.00 and gave the company an “equal weight” rating in a research note on Thursday, October 11th. Two investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $391.67.
NASDAQ ABMD opened at $384.13 on Monday. The stock has a market capitalization of $17.24 billion, a PE ratio of 156.79, a PEG ratio of 4.07 and a beta of 0.35. ABIOMED, Inc. has a 1-year low of $186.72 and a 1-year high of $459.75.
ABIOMED (NASDAQ:ABMD) last released its quarterly earnings data on Thursday, November 1st. The medical equipment provider reported $1.09 earnings per share for the quarter, beating the consensus estimate of $0.73 by $0.36. The business had revenue of $181.78 million for the quarter, compared to analyst estimates of $175.41 million. ABIOMED had a return on equity of 20.09% and a net margin of 27.60%. The company’s revenue was up 36.9% compared to the same quarter last year. During the same period in the previous year, the company posted $0.54 EPS. Sell-side analysts anticipate that ABIOMED, Inc. will post 3.49 earnings per share for the current fiscal year.
In related news, VP Michael G. Howley sold 10,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 25th. The stock was sold at an average price of $432.50, for a total transaction of $4,325,000.00. Following the transaction, the vice president now directly owns 48,954 shares of the company’s stock, valued at approximately $21,172,605. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Andrew J. Greenfield sold 4,440 shares of the business’s stock in a transaction that occurred on Wednesday, August 29th. The stock was sold at an average price of $395.00, for a total value of $1,753,800.00. The disclosure for this sale can be found here. Insiders own 3.50% of the company’s stock.
ABIOMED, Inc engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides continuum of care to heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; and Impella CP, a device used by interventional cardiologists to support patients in the cath lab and cardiac surgeons in the heart surgery suite.
See Also: Why do earnings reports matter?
Want to see what other hedge funds are holding ABMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ABIOMED, Inc. (NASDAQ:ABMD).
Receive News & Ratings for ABIOMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED and related companies with MarketBeat.com's FREE daily email newsletter.